Investigating a new target for treating pulmonary fibrosis
Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis
This study is looking at a protein called Cdk9 to see how it affects lung inflammation and scarring in people with idiopathic pulmonary fibrosis (IPF), with the goal of finding new treatments that can help manage the disease better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11056446 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of cyclin-dependent kinase 9 (Cdk9) in the development of idiopathic pulmonary fibrosis (IPF), a serious lung disease. The researchers aim to identify new drug targets that can improve treatment strategies for IPF, which currently has limited effective therapies. By studying how Cdk9 influences inflammation and fibrosis in lung cells, they hope to develop new medications that can better manage the disease and improve patient outcomes. The approach includes using Cdk9 inhibitors in laboratory models to assess their effectiveness in reducing lung fibrosis and enhancing survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with idiopathic pulmonary fibrosis, potentially improving their quality of life and survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating fibrotic diseases, suggesting that this approach may yield beneficial results.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Haudenschild, Dominik R — Methodist Hospital Research Institute
- Study coordinator: Haudenschild, Dominik R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.